  Network medicine has been pursued for Covid-19 drug repurposing. One such
approach adopts structural controllability, a theory for controlling a network
(the cell). Motivated to protect the cell from viral infections, we extended
this theory to total controllability and introduced a new concept of control
hubs. Perturbation to any control hub renders the cell uncontrollable by
exogenous stimuli, e.g., viral infections, so control hubs are ideal drug
targets. We developed an efficient algorithm for finding all control hubs and
applied it to the largest homogenous human protein-protein interaction network.
Our new method outperforms several popular gene-selection methods, including
that based on structural controllability. The final 65 druggable control hubs
are enriched with functions of cell proliferation, regulation of apoptosis, and
responses to cellular stress and nutrient levels, revealing critical pathways
induced by SARS-CoV-2. These druggable control hubs led to drugs in 4 major
categories: antiviral and anti-inflammatory agents, drugs on central nerve
systems, and dietary supplements and hormones that boost immunity. Their
functions also provided deep insights into the therapeutic mechanisms of the
drugs for Covid-19 therapy, making the new approach an explainable drug
repurposing method. A remarkable example is Fostamatinib that has been shown to
lower mortality, shorten the length of ICU stay, and reduce disease severity of
hospitalized Covid-19 patients. The drug targets 10 control hubs, 9 of which
are kinases that play key roles in cell differentiation and programmed death.
One such kinase is RIPK1 that directly interacts with viral protein nsp12, the
RdRp of the virus. The study produced many control hubs that were not targets
of existing drugs but were enriched with proteins on membranes and the
NF-$\kappa$B pathway, so are excellent candidate targets for new drugs.
